-
CDK Related Products (486)
Related Products (486)
-
Amantadine in Methanol (Standard)
0 ImagesCat. No.: HY-B0402R1CAS No.: 768-94-5Synonyms: 1-Adamantanamine in Methanol (Standard); 1-Aminoadamantane in Methanol (Standard)Amantadine in Methanol (Standard) is the solution of Amantadine (Standard). This product is intended for research and analytical applications. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[4].
-
JNJ-7706621 (Standard)
0 ImagesCat. No.: HY-10329RCAS No.: 443797-96-4JNJ-7706621 (Standard) is the analytical standard of JNJ-7706621 (HY-10329). This product is intended for research and analytical applications. JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively.
-
ZSQ836
0 ImagesCat. No.: HY-164553CAS No.: 2634811-35-9ZSQ836 is an orally active dual covalent inhibitor of CDK12/CDK13, with an EC50 value of 32 nM against CDK12. ZSQ836 can induce apoptosis and exhibit anticancer activity in vivo. ZSQ836 can be used in the study of ovarian cancer.
-
Samuraciclib hydrochloride (Standard)
0 ImagesCat. No.: HY-103712ARCAS No.: 1805789-54-1Synonyms: CT7001 hydrochloride (Standard); ICEC0942 hydrochloride (Standard)Samuraciclib hydrochloride (Standard) is the analytical standard of Samuraciclib hydrochloride (HY-103712A). This product is intended for research and analytical applications. Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib hydrochloride has anti-tumor effects.
-
THZ531 (Standard)
0 ImagesCat. No.: HY-103618RCAS No.: 1702809-17-3
-
CC-671 (Standard)
0 ImagesCat. No.: HY-108709RCAS No.: 1618658-88-0
-
3MB-PP1 (Standard)
0 Images3MB-PP1 (Standard) is the analytical standard of 3MB-PP1 (HY-102069). This product is intended for research and analytical applications. 3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division.
-
AT7519 (Standard)
0 ImagesSynonyms: AT7519M (Standard)
-
Cdc7-IN-1 (Standard)
0 ImagesCdc7-IN-1 (Standard) is the analytical standard of Cdc7-IN-1 (HY-101523). This product is intended for research and analytical applications. Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death.
-
R547 (Standard)
0 ImagesCat. No.: HY-10014RCAS No.: 741713-40-6R547 (Standard) is the analytical standard of R547 (HY-10014). This product is intended for research and analytical applications. R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.
-
PHA-793887 (Standard)
0 ImagesCat. No.: HY-11001RCAS No.: 718630-59-2PHA-793887 (Standard) is the analytical standard of PHA-793887 (HY-11001). This product is intended for research and analytical applications. PHA-793887 is a potent, ATP-competitive CDK inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC50s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase Kinase 3β with an IC50 of 79 nM.
-
CDK8/19-IN-1 (Standard)
0 ImagesCat. No.: HY-111427RCAS No.: 1818427-07-4CDK8/19-IN-1 (Standard) is the analytical standard of CDK8/19-IN-1 (HY-111427). This product is intended for research and analytical applications. CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.
-
AZD-5438 (Standard)
0 ImagesAZD-5438 (Standard) is the analytical standard of AZD-5438. This product is intended for research and analytical applications. AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .
-
DS96432529 (Standard)
0 ImagesDS96432529 (Standard) is the analytical standard of DS96432529 (HY-145121). This product is intended for research and analytical applications. DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis.
-
THZ1 (Standard)
0 ImagesCat. No.: HY-80013RCAS No.: 1604810-83-4THZ1 (Standard) is the analytical standard of THZ1 (HY-80013). This product is intended for research and analytical applications. THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 also inhibits the closely related Kinases CDK12 and CDK13 and downregulates MYC expression.
-
(R)-Roscovitine (Standard)
0 ImagesCat. No.: HY-30237RCAS No.: 186692-46-6Synonyms: Seliciclib (Standard); CYC202 (Standard)(R)-Roscovitine (Standard) is the analytical standard of (R)-Roscovitine (HY-30237). This product is intended for research and analytical applications. (R)-Roscovitine (Seliciclib) is an orally bioavailable, selective and BBB-permeable CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
-
Romaciclib monohydrochloride (Standard)
0 ImagesCat. No.: HY-111388ARCAS No.: 2443816-41-7Synonyms: SEL120-34A monohydrochloride (Standard)Romaciclib monohydrochloride (Standard) is the analytical standard of Romaciclib (monohydrochloride) (HY-111388A). This product is intended for research and analytical applications. SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits Kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726. Has anti-tumor activity.
-
Dehydrodiisoeugenol (Standard)
0 ImagesDehydrodiisoeugenol (Standard) is the analytical standard of Dehydrodiisoeugenol (HY-N0589). This product is intended for research and analytical applications. Dehydrodiisoeugenol is an orally active anti-inflammatory and anti-tumor agent. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells, and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol also exerts anti-inflammatory effects by inhibiting the activation of NF-κB and the expression of COX-2. Dehydrodiisoeugenol can be used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis.
-
CLK1-IN-1 (Standard)
0 ImagesCat. No.: HY-103082RCAS No.: 2123491-32-5
